Ensure timely and compliant study and site close‑out activities across Ipsen’s portfolio. Maintain continuous inspection readiness at site and country level, including oversight of:
- TMF completeness and quality (in collaboration with TMF leadership)
- Site documentation and essential document quality
- Inspection preparedness activities with FSP partners and internal stakeholders
- Support country focused regulatory inspections and audits, acting as a senior sponsor representative for Study, Site Management and Monitoring matters.
- Site Engagement Strategy
At country/cluster level, own and implement Ipsen’s Site Engagement Strategy, aligned to clinical development priorities, therapeutic focus, and portfolio growth. Establish a structured approach to understanding Ipsen’s site landscape using it to lead the identification of priority and strategic sites, differentiating:
- High‑performing operational delivery sites.
- Emerging or development sites critical to pipeline growth
- Sites in new/emerging Therapeutic Areas
- Be accountable for the health of investigator sites, including performance, recruitment/retention and quality
Partner with key stakeholders (e.g. Local Medical Affairs)) to ensure that a robust, differentiated site engagement strategy is put into place. May include coordinating with global patient affairs to facilitate regional patient input into clinical trials. Own study level site segmentation strategy at country/cluster and, where necessary, will co-ordinate site segmentation plan for an asset globally
Where appropriate partner with external groups like Patient Advocacy Groups to optimise access to subjects and to support site performance
Understand the in-cluster capabilities and effectively communicate them to support the global strategy e.g. access to country specific registries, diagnostic testing pathways including planned policy changes.